Efficacy & Safety of Patritumab Deruxtecan for EGFR+ NSCLC – 2022 Program: Targeted Therapies Forum

Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses the use of Patritumab Deruxtecan for EGFR+ NSCLC.

We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech

For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.